Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)
Phase of Trial: Phase I
Latest Information Update: 16 May 2018
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 May 2018 Planned End Date changed from 4 Sep 2018 to 4 Oct 2018.
- 07 May 2018 Planned primary completion date changed from 4 Sep 2018 to 4 Oct 2018.
- 07 May 2018 Status changed from not yet recruiting to recruiting.